By Robb M. Stewart
Lantheus's shares were under pressure Wednesday after the radiopharmaceutical-focused company trimmed its earnings target for the year.
In premarket trading, the shares were 13% lower after ending the previous session at $104.84, up 17% so far in 2025 and 38% higher over the last 12 months.
The company lowered its guidance for the adjusted earnings in 2025 to between $6.60 and $6.70 a share on revenue of $1.55 billion to about $1.59 billion. In late February, it was aiming for earnings of $7 to $7.20 on revenue of between about $1.55 billion and $1.61 billion.
Lantheus recorded net income of $72.9 million, or $1.02 a share, for the first quarter, down sharply from $131.1 million, or $1.87 a share, a year earlier.
On an adjusted basis, per-share earnings came in at $1.53, below the $1.66 mean estimate of analysts polled by FactSet.
The company's worldwide revenue was little changed for the quarter, edging up less than 1% to $372.8 million but falling short of the $379.7 million that analysts expected.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 07, 2025 08:54 ET (12:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。